Immorta Bio, Inc.
Personalized progenitor cell therapies for aging-related diseases
- Sector
- Biotech
- Headquarters
- MIAMI BEACH, FL
- Founded
- 2023
- Latest Form D
- $613K, Oct 2026
- Total capital
- $1.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $1.1M
- 2 Form D · last Oct 2026
- 0 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 31 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$613K
- Private capital raisedForm D · SEC · 1st filing$450K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Boris ReznikExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 31- PendingEndothelial Stimulation Of Hepatic RegenerationUSPTOApplication PCTUS2025048296
- PendingStimulation Of Hematopoiesis And Stem Cell Engraftment By SenolysisUSPTOApplication PCTUS2025043595
- PendingReduction Of Senescent Cell Associated Aging And PathologyUSPTOApplication PCTUS2025038369
Show all 31 patent records
- Endothelial Stimulation Of Hepatic RegenerationApplication PCTUS2025048296Pending
- Stimulation Of Hematopoiesis And Stem Cell Engraftment By SenolysisApplication PCTUS2025043595Pending
- Reduction Of Senescent Cell Associated Aging And PathologyApplication PCTUS2025038369Pending
- Natural Antibody-mediated Clearing Of Senescent CellsApplication PCTUS2025038367Pending
- Enhancement Of Regenerative Activity By Inactivation Of Senescent CellsApplication PCTUS2025034047Pending
- Pluripotent Stem Cell Derived Mesenchymal Stem Cells With Enhanced Immune Modulatory ActivityApplication PCTUS2025028946Pending
- Treatment Of Liver Failure By Hepatogenic MonocytesApplication PCTUS2025028377Pending
- Senescent Cell Targeting T Cell Responses By Ex Vivo Generated Antigen Presenting CellsApplication PCTUS2025025864Pending
- Senescence VaccineApplication PCTUS2025018210Pending
- Systemic Means Of DedifferentiationApplication PCTUS2025014195Pending
- Therapeutic Use Of Autologous Pluripotent Stem Cell And Differentiated Cell ExosomesApplication PCTUS2025014201Pending
- Reprogrammed Cell Modulation Of Cancer Microenvironment By Tumor Homing Personalized Regenerative CellsApplication PCTUS2024061565Pending
- Genetic Modification Of Personalized Regenerative CellsApplication PCTUS2024061489Pending
- Treatment Of Heart Failure Using Pluripotent Stem Cell Derived Cardiomyocytes And Derivatives ThereofApplication PCTUS2024057335Pending
- Treatment Of Multiorgan Failure With Autologous Pluripotent Stem Cell Derived TherapiesApplication PCTUS2024057339Pending
- Treatment Of Liver Failure Using Personalized Progenitor Cells And Derivatives ThereofApplication PCTUS2024057338Pending
- Generation Of Personalized Mesenchymal Stem CellsApplication PCTUS2024055915Pending
- Personalized Progenitor CellsApplication PCTUS2024055924Pending
- Personalized Regenerative CellsApplication PCTUS2024051719Pending
- Treatment Of Liver Failure Using Personalized Progenitor Cells And Derivatives ThereofApplication 19591585Pending
- Treatment Of Heart Failure Using Pluripotent Stem Cell Derived Cardiomyocytes And Derivatives ThereofApplication 19591575Pending
- Genetic Modification Of Personalized Regenerative CellsApplication 19602274Pending
- Personalized Regenerative CellsApplication 19579388Pending
- Treatment Of Multiorgan Failure With Autologous Pluripotent Stem Cell Derived TherapiesApplication 19591590Pending
- Generation Of Personalized Mesenchymal Stem CellsApplication 19588096Pending
- Systemic Rejuvenation Using Exosomes Derived From Autologous Dedifferentiated Regenerative CellsApplication PCTUS2026018036Pending
- Senescence VaccineApplication 19625359Pending
- Personalized Progenitor CellsApplication 19588080Pending
- Systemic Means of DedifferentiationApplication 19611930Pending
- Reprogrammed Cell Modulation Of Cancer Microenvironment By Tumor Homing Personalized Regenerative CellsApplication 19601410Pending
- Therapeutic Use Of Autologous Pluripotent Stem Cell And Differentiated Cell ExosomesApplication 19611913Pending
Related companies, and why
- TORL BioTherapeuticsSimilar federal contract value in Biotech · null in contracts
- Axelyf, Inc.Similar federal contract value in Biotech · null in contracts
- CURADEL SURGICAL INNOVATIONS, INC.Similar federal contract value in Biotech · null in contracts
- AraviveSimilar federal contract value in Biotech · null in contracts
- SonoTheraSimilar federal contract value in Biotech · null in contracts
- Entrada TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .